Ji-Chuan decoction ameliorates slow transit constipation via regulation of intestinal glial cell apoptosis

Figure 4 Network construction, screening and validation of the core targets for Ji-Chuan decoction treatment of slow transit constipation. A: Protein-protein interaction (PPI) network; B: Top 30 protein targets with the largest betweenness in the PPI network; C: Betweenness analysis of the top 30 protein targets; D and E: The relative expression of AKT as assessed by immunofluorescent staining. AKT: Serine/threonine-protein kinase; HC: Healthy control; STC: Slow transit constipation; JCD: Ji-Chuan decoction; JCDL: Low-dose Ji-Chuan decoction treatment; JCDM: Middle-dose Ji-Chuan decoction treatment; JCDH: High-dose Ji-Chuan decoction treatment; MSP: Mosapride treatment; SLC6A4: Sodium-dependent serotonin transporter; AKT1: RAC-alpha serine/threonine-protein kinase; IL: Interleukin; NQO1: NAD(P)H dehydrogenase (quinone)1; GABRB2: Gammaaminobutyric acid receptor subunit beta-2; CASP3: Caspase-3; CAT: Catalase; ESR1: Estrogen receptor; MAPK3: Mitogen-activated protein kinase 3; FOS: Proto-oncogene c-Fos; VEGFA: Vascular endothelial growth factor A; EGFR: Epidermal growth factor receptor; EGF: Pro-epidermal growth factor; CAV1: Caveolin-1; JUN: Transcription factor AP-1; PTGS2: Prostaglandin G/H synthase 2; MAPK8: Mitogen-activated protein kinase 8; MYC: Myc proto-oncogene protein; MAPK1: Mitogen-activated protein kinase 1; CCND1: G1/S-specific cyclin-D1; CREB1: Cyclic AMP-responsive element-binding protein 1; TH: Thyroid hormone; CYCS: Cytochrome c; HMOX1: Heme oxygenase 1; MMP9: Matrix metalloproteinase-9; ERBB2: Receptor tyrosine-protein kinase erbB-2; FN1: Fibronectin. Data are expressed as the mean ± SD. Compared with the healthy control group: ^bP < 0.01. Compared with the slow transit constipation group: ^cP < 0.05, ^dP < 0.01.